Symbols / QNTM Stock $3.61 +12.46% Quantum BioPharma Ltd.
QNTM (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Ratings
Current target
$3.61
Low
$12.78
High
$12.78
Mean
$12.78
- Hangover remedy maker Unbuzzd picks CEO for rollout in Florida and Texas - Stock Titan Wed, 22 Apr 2026 13
- Quantum BioPharma Ltd. Closes Initial Tranche of Offering and Completes Debt Settlement | QNTM Stock News - Quiver Quantitative Fri, 20 Mar 2026 07
- Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - ChartMill Wed, 22 Apr 2026 13
- Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - Sahm Wed, 22 Apr 2026 07
- QNTM Should I Buy - Intellectia AI Sat, 28 Feb 2026 19
- Quantum (QNTM) Stock: Momentum Behavior Insight (Slight Rise) 2026-04-20 - Shared Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 14
- Quantum BioPharma Ltd. to Release Financial Results and Announce Private Placement Offering | QNTM Stock News - Quiver Quantitative ue, 10 Mar 2026 07
- New MS treatment targeting demyelination moves toward Phase 2 - Stock Titan Mon, 30 Mar 2026 07
- Quantum BioPharma Ltd. Faces Class Action Lawsuit Over Allegations of Stock Manipulation - Quiver Quantitative Mon, 22 Dec 2025 08
- [6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC Filing - Form 6-K - Stock Titan hu, 02 Apr 2026 07
- After drinking, this supplement cut headache severity 67% in trial - Stock Titan Mon, 23 Mar 2026 07
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied - Stock Titan hu, 02 Apr 2026 07
- Quantum BioPharma (QNTM) advances Lucid-MS plan, details unbuzzd™ royalties and tax assets - Stock Titan hu, 26 Mar 2026 07
- [6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC Filing - Form 6-K - Stock Titan Fri, 27 Mar 2026 07
- Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan Wed, 01 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.32
-3.57%
|
15.88
-18.84%
|
19.57
-28.65%
|
27.43
|
| Research And Development |
|
2.76
-54.58%
|
6.08
+57.63%
|
3.86
-44.16%
|
6.91
|
| Selling General And Administration |
|
12.01
+28.98%
|
9.31
-29.49%
|
13.20
-17.37%
|
15.98
|
| General And Administrative Expense |
|
12.01
+28.98%
|
9.31
-29.49%
|
13.20
-17.37%
|
15.98
|
| Salaries And Wages |
|
5.15
+83.23%
|
2.81
-50.61%
|
5.69
+271.63%
|
1.53
|
| Other Gand A |
|
6.86
+5.53%
|
6.50
-13.50%
|
7.51
-48.00%
|
14.45
|
| Total Expenses |
|
15.32
-3.57%
|
15.88
-18.84%
|
19.57
-28.65%
|
27.43
|
| Operating Income |
|
-15.32
+3.57%
|
-15.88
+18.84%
|
-19.57
+28.65%
|
-27.43
|
| Total Operating Income As Reported |
|
-15.30
+5.17%
|
-16.14
+32.17%
|
-23.79
+13.27%
|
-27.43
|
| EBITDA |
|
-25.79
-79.40%
|
-14.38
+8.56%
|
-15.72
+28.91%
|
-22.12
|
| Normalized EBITDA |
|
-14.08
+4.98%
|
-14.82
-30.68%
|
-11.34
+49.39%
|
-22.41
|
| Reconciled Depreciation |
|
0.55
+11.25%
|
0.49
-80.43%
|
2.51
-44.73%
|
4.53
|
| EBIT |
|
-26.34
-77.15%
|
-14.87
+18.44%
|
-18.23
+31.61%
|
-26.65
|
| Total Unusual Items |
|
-11.71
-2766.90%
|
0.44
+110.01%
|
-4.39
-1624.97%
|
0.29
|
| Total Unusual Items Excluding Goodwill |
|
-11.71
-2766.90%
|
0.44
+110.01%
|
-4.39
-1624.97%
|
0.29
|
| Special Income Charges |
|
0.04
-94.08%
|
0.73
+116.08%
|
-4.56
|
0.00
|
| Other Special Charges |
|
-0.04
+94.08%
|
-0.73
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
|
0.00
-100.00%
|
4.56
|
0.00
|
| Net Income |
|
-26.18
-84.30%
|
-14.20
+20.66%
|
-17.90
+24.17%
|
-23.61
|
| Pretax Income |
|
-26.96
-80.73%
|
-14.92
+18.18%
|
-18.23
+31.73%
|
-26.70
|
| Net Non Operating Interest Income Expense |
|
-0.38
-172.82%
|
0.53
-33.17%
|
0.79
+146.48%
|
0.32
|
| Interest Expense Non Operating |
|
0.62
+1200.29%
|
0.05
+15812.04%
|
0.00
-99.39%
|
0.05
|
| Net Interest Income |
|
-0.38
-172.82%
|
0.53
-33.17%
|
0.79
+146.48%
|
0.32
|
| Interest Expense |
|
0.62
+1200.29%
|
0.05
+15812.04%
|
0.00
-99.39%
|
0.05
|
| Interest Income Non Operating |
|
0.24
-58.79%
|
0.57
-27.15%
|
0.79
+113.84%
|
0.37
|
| Interest Income |
|
0.24
-58.79%
|
0.57
-27.15%
|
0.79
+113.84%
|
0.37
|
| Other Income Expense |
|
-11.26
-2639.96%
|
0.44
-19.92%
|
0.55
+35.97%
|
0.41
|
| Other Non Operating Income Expenses |
|
0.46
+11336.78%
|
0.00
-99.92%
|
4.94
+4034.69%
|
0.12
|
| Gain On Sale Of Security |
|
-11.76
-3909.49%
|
-0.29
-272.22%
|
0.17
-40.80%
|
0.29
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.96
-80.73%
|
-14.92
+18.18%
|
-18.23
+22.77%
|
-23.61
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.18
-84.30%
|
-14.20
+20.66%
|
-17.90
+32.96%
|
-26.70
|
| Net Income From Continuing And Discontinued Operation |
|
-26.18
-84.30%
|
-14.20
+20.66%
|
-17.90
+24.17%
|
-23.61
|
| Net Income Continuous Operations |
|
-26.96
-80.73%
|
-14.92
+18.18%
|
-18.23
+31.73%
|
-26.70
|
| Net Income Discontinuous Operations |
|
—
|
0.00
|
0.00
-100.00%
|
3.10
|
| Minority Interests |
|
0.78
+9.64%
|
0.71
+117.05%
|
0.33
|
0.00
|
| Normalized Income |
|
-14.46
+1.23%
|
-14.64
-8.33%
|
-13.52
+49.92%
|
-26.99
|
| Net Income Common Stockholders |
|
-26.18
-84.30%
|
-14.20
+20.66%
|
-17.90
+24.17%
|
-23.61
|
| Diluted EPS |
|
-8.20
+37.50%
|
-13.12
+56.16%
|
-29.93
+24.44%
|
-39.61
|
| Basic EPS |
|
-8.20
+37.50%
|
-13.12
+56.16%
|
-29.93
+24.44%
|
-39.61
|
| Basic Average Shares |
|
3.29
+189.02%
|
1.14
+86.67%
|
0.61
+2.21%
|
0.60
|
| Diluted Average Shares |
|
3.29
+189.02%
|
1.14
+86.67%
|
0.61
+2.21%
|
0.60
|
| Diluted NI Availto Com Stockholders |
|
-26.18
-84.30%
|
-14.20
+20.66%
|
-17.90
+24.17%
|
-23.61
|
| Depreciation Amortization Depletion Income Statement |
|
0.55
+11.25%
|
0.49
-80.43%
|
2.51
-44.76%
|
4.54
|
| Depreciation And Amortization In Income Statement |
|
0.55
+11.25%
|
0.49
-80.43%
|
2.51
-44.76%
|
4.54
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
17.47
|
| Current Assets |
|
11.09
|
| Cash Cash Equivalents And Short Term Investments |
|
3.51
|
| Cash And Cash Equivalents |
|
2.76
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
0.76
|
| Receivables |
|
7.42
|
| Other Receivables |
|
0.00
|
| Taxes Receivable |
|
0.21
|
| Accrued Interest Receivable |
|
0.02
|
| Loans Receivable |
|
7.19
|
| Inventory |
|
0.00
|
| Raw Materials |
|
—
|
| Finished Goods |
|
—
|
| Prepaid Assets |
|
0.16
|
| Restricted Cash |
|
—
|
| Assets Held For Sale Current |
|
—
|
| Other Current Assets |
|
—
|
| Total Non Current Assets |
|
6.39
|
| Net PPE |
|
0.12
|
| Gross PPE |
|
0.12
|
| Other Properties |
|
0.12
|
| Goodwill And Other Intangible Assets |
|
5.36
|
| Other Intangible Assets |
|
5.36
|
| Investments And Advances |
|
0.01
|
| Other Investments |
|
0.01
|
| Non Current Accounts Receivable |
|
0.91
|
| Total Liabilities Net Minority Interest |
|
4.57
|
| Current Liabilities |
|
4.57
|
| Payables And Accrued Expenses |
|
4.20
|
| Payables |
|
3.24
|
| Accounts Payable |
|
3.24
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
0.95
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.34
|
| Current Debt |
|
0.30
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.04
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Stockholders Equity |
|
13.24
|
| Common Stock Equity |
|
13.24
|
| Capital Stock |
|
137.78
|
| Common Stock |
|
137.78
|
| Share Issued |
|
0.61
|
| Ordinary Shares Number |
|
0.61
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
30.23
|
| Retained Earnings |
|
-157.91
|
| Gains Losses Not Affecting Retained Earnings |
|
0.42
|
| Minority Interest |
|
-0.33
|
| Total Equity Gross Minority Interest |
|
12.91
|
| Total Capitalization |
|
13.24
|
| Working Capital |
|
6.52
|
| Invested Capital |
|
13.54
|
| Total Debt |
|
0.34
|
| Capital Lease Obligations |
|
0.04
|
| Net Tangible Assets |
|
7.88
|
| Tangible Book Value |
|
7.88
|
| Available For Sale Securities |
|
0.01
|
| Current Notes Payable |
|
0.30
|
| Foreign Currency Translation Adjustments |
|
0.42
|
| Interest Payable |
|
0.41
|
| Investmentin Financial Assets |
|
0.01
|
| Non Current Note Receivables |
|
0.91
|
| Other Equity Interest |
|
2.72
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.24
-19.79%
|
-6.88
+36.49%
|
-10.83
+61.79%
|
-28.33
|
| Cash Flow From Continuing Operating Activities |
|
-8.24
-19.79%
|
-6.88
+36.49%
|
-10.83
+60.18%
|
-27.19
|
| Cash From Discontinued Operating Activities |
|
—
|
0.00
|
0.00
+100.00%
|
-1.14
|
| Net Income From Continuing Operations |
|
-26.96
-80.73%
|
-14.92
+18.18%
|
-18.23
+31.73%
|
-26.70
|
| Depreciation Amortization Depletion |
|
0.55
+11.25%
|
0.49
-80.43%
|
2.51
-44.73%
|
4.53
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
0.55
+11.25%
|
0.49
-80.43%
|
2.51
-44.73%
|
4.53
|
| Other Non Cash Items |
|
2.13
+8826.60%
|
0.02
-1.59%
|
0.02
-40.46%
|
0.04
|
| Stock Based Compensation |
|
2.95
+1835.11%
|
0.15
-96.03%
|
3.84
+150.48%
|
1.53
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
4.56
|
0.00
|
| Operating Gains Losses |
|
10.60
+518.85%
|
-2.53
+54.29%
|
-5.53
-1990.05%
|
0.29
|
| Gain Loss On Investment Securities |
|
11.14
+10762.42%
|
-0.10
+97.97%
|
-5.15
-703.30%
|
-0.64
|
| Unrealized Gain Loss On Investment Securities |
|
0.51
+253.27%
|
0.15
-61.56%
|
0.38
+61.56%
|
0.23
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.50
+70.39%
|
-1.69
-341.40%
|
-0.38
-141.06%
|
0.93
|
| Change In Working Capital |
|
1.99
-79.65%
|
9.76
+495.72%
|
1.64
+123.00%
|
-7.12
|
| Change In Receivables |
|
1.69
-62.64%
|
4.52
+719.87%
|
-0.73
+89.90%
|
-7.22
|
| Change In Inventory |
|
0.07
+155.53%
|
-0.12
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
0.05
-37.78%
|
0.09
-72.73%
|
0.32
-60.21%
|
0.80
|
| Change In Payables And Accrued Expense |
|
1.18
-72.40%
|
4.27
+108.33%
|
2.05
+392.92%
|
-0.70
|
| Change In Payable |
|
1.18
-72.40%
|
4.27
+108.33%
|
2.05
+392.92%
|
-0.70
|
| Change In Other Working Capital |
|
-1.00
-200.00%
|
1.00
|
—
|
—
|
| Investing Cash Flow |
|
-1.95
-29.86%
|
-1.50
-457.74%
|
-0.27
-102.22%
|
12.12
|
| Cash Flow From Continuing Investing Activities |
|
-1.95
-29.86%
|
-1.50
-457.74%
|
-0.27
+55.63%
|
-0.61
|
| Cash From Discontinued Investing Activities |
|
—
|
0.00
|
0.00
-100.00%
|
12.73
|
| Net PPE Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.11
|
| Purchase Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.11
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.36
|
| Net Investment Purchase And Sale |
|
-1.95
-29.86%
|
-1.50
-398.92%
|
-0.30
-23.72%
|
-0.24
|
| Purchase Of Investment |
|
-6.09
+20.77%
|
-7.69
-933.26%
|
-0.74
-85.38%
|
-0.40
|
| Sale Of Investment |
|
4.14
-33.07%
|
6.19
+1296.65%
|
0.44
+180.40%
|
0.16
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
0.03
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.25
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-0.25
|
| Financing Cash Flow |
|
6.10
-47.51%
|
11.62
+471.61%
|
-3.13
-51.09%
|
-2.07
|
| Cash Flow From Continuing Financing Activities |
|
6.10
-47.51%
|
11.62
+471.61%
|
-3.13
-51.09%
|
-2.07
|
| Net Issuance Payments Of Debt |
|
5.24
+452.88%
|
0.95
+601.58%
|
-0.19
-32.14%
|
-0.14
|
| Issuance Of Debt |
|
5.36
+429.39%
|
1.01
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-0.11
-79.07%
|
-0.06
+66.37%
|
-0.19
-32.14%
|
-0.14
|
| Long Term Debt Payments |
|
-0.11
-79.07%
|
-0.06
+66.37%
|
-0.19
-32.14%
|
-0.14
|
| Net Long Term Debt Issuance |
|
-0.11
-79.07%
|
-0.06
+66.37%
|
-0.19
-32.14%
|
-0.14
|
| Short Term Debt Issuance |
|
5.36
+429.39%
|
1.01
|
0.00
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
|
0.00
|
| Net Short Term Debt Issuance |
|
5.36
+429.39%
|
1.01
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
0.34
-96.83%
|
10.67
+460.76%
|
-2.96
-53.55%
|
-1.93
|
| Common Stock Payments |
|
0.00
|
0.00
+100.00%
|
-2.96
-53.55%
|
-1.93
|
| Repurchase Of Capital Stock |
|
0.00
|
0.00
+100.00%
|
-2.96
-53.55%
|
-1.93
|
| Proceeds From Stock Option Exercised |
|
0.19
|
0.00
-100.00%
|
0.02
|
0.00
|
| Net Other Financing Charges |
|
0.33
|
—
|
—
|
—
|
| Changes In Cash |
|
-4.09
-226.30%
|
3.24
+122.77%
|
-14.22
+22.19%
|
-18.28
|
| Beginning Cash Position |
|
6.00
+117.47%
|
2.76
-83.76%
|
16.98
-51.84%
|
35.26
|
| End Cash Position |
|
1.91
-68.22%
|
6.00
+117.47%
|
2.76
-83.76%
|
16.98
|
| Free Cash Flow |
|
-8.24
-19.79%
|
-6.88
+36.49%
|
-10.83
+62.27%
|
-28.70
|
| Common Stock Issuance |
|
0.34
-96.83%
|
10.67
+31384070.59%
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.34
-96.83%
|
10.67
+31384070.59%
|
0.00
|
0.00
|
| Sale Of Business |
|
0.00
|
0.00
-100.00%
|
0.03
|
0.00
|
| Cash From Discontinued Financing Activities |
|
—
|
—
|
—
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|